Increased BIRC6 protein level may be a predictive factor for chemoresistance and an adverse prognostic marker for NSCLC, and inhibiting BIRC6 may be a useful method for treating the tumor [44]. This evidence concerns the gene BIRC6 and non-small cell lung carcinoma.